Covid-19 Serosurveillance Positivity in General Population: Comparison at Different Times

Om  Prakash; Bhavin  Solanki; Jay K  Sheth; Chirag  Shah; Mina  Kadam; Sheetal  Vyas; Aparajita  Shukla; Hemant  Tiwari

doi:10.5455/njcm.20210518084014

Authors

Om Prakash Deputy Municipal Commissioner Health Department AMC Ahmedabad
Bhavin Solanki Medical Officer of Health Health Department AMC Ahmedabad
Jay K Sheth Department of Community Medicine AMC MET Medical College Ahmedabad
Chirag Shah Deputy Health Officer Health Department AMC Ahmedabad
Mina Kadam AMC MET Medical College Ahmedabad
Sheetal Vyas AMC MET Medical College Ahmedabad
Aparajita Shukla NHL Municipal Medical College Ahmedabad
Hemant Tiwari NHL Municipal Medical College Ahmedabad

DOI:

https://doi.org/10.5455/njcm.20210518084014

Keywords:

SARS-COV2, Covid-19, Sero-surveillance, IgG Antibody, Immunity

Abstract

Introduction: Serological surveys estimating the cumulative incidence of the disease are powerful and effective tools for monitoring the epidemic and in determining the immunity status.

Objectives: To compare the percentage sero-positivity for IgG antibodies against SARS-CoV2 at two different time period in the same population to understand the pandemic and predict about the immunity status of the population.

Methods: As a part of Covid19 pandemic management, two separate population based sero-survey within a gap of 1½ months were carried in Ahmedabad city to scientifically document the progress of the Covid19 pandemic. Various demographic factors and other parameters from both the survey were compared with seropositivity for valid and precise estimation of disease situation as well as immunity status of the population.

Results: The study documents an increase in seropositivity by 5.32% (from 17.92% to 23.24%). The seropositivity shows increasing trend with increase in the age group and the seropositivity is significantly higher among females. Overall higher seropositivity against the reported cases in the first sero-survey and the narrow increase in the seropositivity during the subsequent sero-survey inspite of high number of cases may indicate temporary status of the antibodies. This may also be due to the difference in the level of stigma, health care service delivery, service utilization and related field level situation affecting the asymptomatic/unreported case positivity.

Conclusion: The result of seropositivity comparison indicates the scopes for further research to confirm and generate greater evidences regarding the factors affecting seropositivity.

References

Munster VJ, Koopmans M, van Doremalen N, van Riel D, de Wit E. A novel coronavirus emerging in China—key questions for impact assessment. New England Journal of Medicine. 2020 Feb 20;382(8):692-4.

Li Q, Guan X, Wu P, Wang X, Zhou L, Tong Y, Ren R, Leung KS, Lau EH, Wong JY, Xing X. Early transmission dynamics in Wu-han, China, of novel coronavirus–infected pneumonia. New England Journal of Medicine. 2020 Jan 29.

Lipsitch M, Swerdlow DL, Finelli L. Defining the epidemiology of Covid-19—studies needed. New England journal of medi-cine. 2020 Mar 26;382(13):1194-6.

Swaminathan A, Subramanian SV. Reflections on designing population surveys for COVID-19 infection and prevalence. GeroScience. Springer; 2020. [cited 2020 Sep 4]. p. 1–4. Avail-able from: 10.1007/s11357-020-00253-6

Cohn J. Unprecedented nationwide blood studies seek to track U.S. coronavirus spread. Sciencemag.org 2020. doi:10.1126/ science.abc1319

World Health Organization. (2020). Population-based age-stratified seroepidemiological investigation protocol for COVID-19 virus infection, 17 March 2020. World Health Or-ganization. Available from: https://apps.who.int/iris/ han-dle/ 10665/ 331656. License: CC BY-NC-SA 3.0 IGO.

Hanage, William, Xueting Qiu, Lee Kennedy-Shaffer. Snowball Sampling Study Design for Serosurveys in the Early COVID-19 Pandemic (2020).

Xu, X., Sun, J., Nie, S. et al. Seroprevalence of immunoglobulin M and G antibodies against SARS-CoV2 in China. Nat Med 26, 1193–1195 (2020). https://doi.org/10.1038/s41 591-020-0949-6

Murhekar MV, Bhatnagar T, Selvaraju S, Rade K, Sara-vanakumar V, Vivian Thangaraj JW, et al. Prevalence of SARS‑CoV‑2 infection in India: Findings from the national se-rosurvey, May‑June 2020. Indian J Med Res 2020;152:48‑60.

Indian Council of Medical Research. Press Release ICMR Ad-vises States to Conduct Sero-Survey to Measure Coronavirus Exposure in the Population Using IgG ELISA Test.; 2020. Ac-cessed February 4, 2021. https://main.icmr.nic.in/sites /default/files/press_realease_files/ ICMR_PR_IgG_Elisa_30052020.pdf

The Economic Times. Prevalence of Covid-19 infection, at 55%, is the highest in Ahmedabad containment zones: The Economic times. Available from https://economictimes. indi-atimes.com/industry/healthcare/biotech/healthcare/prevalence-at-55-highest-in-abad-containment-zones/articles how/77073909.cms?from=mdr

Prakash O, Solanki B, Sheth JK, et al. Assessing seropositivity for IgG antibodies against SARS-CoV-2 in Ahmedabad city of India: a cross-sectional study. BMJ Open 2021;11:e044101. doi: 10.1136/bmjopen-2020-044101

Prakash O, Solanki B, Sheth JK, et al. Population based sero-positivity for IgG antibodies against SARS-CoV2 in Ahmeda-bad city. J Family Med Prim Care 2021. Forthcoming 10(6).

Tripathi SC, Deshmukh V, Patil A, et al. COVID 19 diagnostic multiplicity and its role in community surveillance and con-trol. InfezMed 2020;28:18–28.

Zhao J, Yuan Q, Wang H, et al. Antibody responses to SARS-CoV-2 in patients with novel coronavirus disease 2019. Clin Infect Dis. 2020;71:2027–34.

Rostami A, Sepidarkish M, Leeflang MMG, et al. SARS-CoV-2 seroprevalence worldwide: a systematic review and meta-analysis. Clin Microbiol Infect. 2021;27(3):331-340. doi:10.1016/j.cmi.2020.10.020

Lai CC, Wang JH, Hsueh PR. Population-based seroprevalence surveys of anti-SARS-CoV-2 antibody: An up-to-date re-view. Int J Infect Dis. 2020;101:314-322. doi:10.1016/j.i jid.2020.10.011

Hallal PC, Hartwig FP, Horta BL, Silveira MF, Struchiner CJ, Vidaletti LP, Neumann NA, Pellanda LC, Dellagostin OA, Burat-tini MN, Victora GD. SARS-CoV-2 antibody prevalence in Bra-zil: results from two successive nationwide serological household surveys. The Lancet Global Health. 2020 Nov 1;8(11):e1390-8.

Silveira, M.F., Barros, A.J.D., Horta, B.L. et al. Population-based surveys of antibodies against SARS-CoV-2 in Southern Bra-zil. Nat Med 26, 1196–1199 (2020). https://doi.org/ 0.1038/s41591-020-0992-3

Orlowski EJW, Goldsmith DJA. Four months into the COVID-19 pandemic, Sweden's prized herd immunity is nowhere in sight. J R Soc Med. 2020;113(8):292-298. doi:10.1177 /0141076820945282.

Bryant JE, Azman AS, Ferrari MJ, et al. Serology for SARS-CoV-2: Apprehensions, opportunities, and the path forward. Sci Immunol. 2020;5(47):eabc6347. doi:10.1126/ sciimmunol. abc6347

Stringhini S, Wisniak A, Piumatti G, et al. Seroprevalence of anti-SARS-CoV-2 IgG antibodies in Geneva, Switzerland (SE-ROCoV-POP): a population-based study. Lancet. 2020;396(10247):313-319. doi:10.1016/S0140-6736(20) 31304-0

Wang X, Guo X, Xin Q, et al. Neutralizing Antibody Responses to Severe Acute Respiratory Syndrome Coronavirus 2 in Coronavirus Disease 2019 Inpatients and Convalescent Pa-tients. Clin Infect Dis. 2020;71(10):2688-2694. doi:10.1093 /cid/ciaa721

Xiao T, Wang Y, Yuan J, et al. Early Viral Clearance and Anti-body Kinetics of COVID-19 Among Asymptomatic Carri-ers. Front Med (Lausanne). 2021;8:595773. doi:10.3389 /fmed.2021.595773

Hu WT, Howell JC, Ozturk T, et al. Antibody Profiles Accord-ing to Mild or Severe SARS-CoV-2 Infection, Atlanta, Georgia, USA, 2020. Emerg Infect Dis. 2020;26(12):2974-2978. doi:10.3201/eid2612.203334

Cervia C, Nilsson J, Zurbuchen Y, et al. Systemic and mucosal antibody responses specific to SARS-CoV-2 during mild ver-sus severe COVID-19. J Allergy Clin Immunol. 2021; 147(2):545-557.e9. doi:10.1016/j.jaci.2020.10.040

Okba NMA, Müller MA, Li W, et al. Severe Acute Respiratory Syndrome Coronavirus 2-Specific Antibody Responses in Coronavirus Disease Patients. Emerg Infect Dis. 2020;26(7): 1478-1488. doi:10.3201/eid2607.200841

Shakiba M, Nazemipour M, Salari A, et al. Seroprevalence of SARS-CoV-2 in Guilan Province, Iran, April 2020. Emerg Infect Dis. 2021;27(2):636-638. doi:10.3201/eid2702.201960

Huang L, Zhang X, Zhang X, et al. Rapid asymptomatic trans-mission of COVID-19 during the incubation period demon-strating strong infectivity in a cluster of youngsters aged 16-23 years outside Wuhan and characteristics of young patients with COVID-19: A prospective contact-tracing study. J Infect. 2020;80(6):e1-e13. doi:10.1016/j.jinf.2020.03.006

Bendavid E, Mulaney B, Sood N, et al. COVID-19 antibody se-roprevalence in Santa Clara County, California. Int J Epidemiol. 2021;50(2):410-419. doi:10.1093/ije/dyab010

Seow J, Graham C, Merrick B, et al. Longitudinal observation and decline of neutralizing antibody responses in the three months following SARS-CoV-2 infection in humans. Nat Mi-crobiol. 2020;5(12):1598-1607. doi:10.1038/s41564-020-00813-8

Sethuraman N, Jeremiah SS, Ryo A. Interpreting Diagnostic Tests for SARS-CoV-2. JAMA. 2020;323(22):2249-2251. doi:10.1001/jama.2020.8259